LATEST

• BUSINESS Mikasa Bags Japan Rights to AFT’s Maxigesic IV
  September 29, 2026

• BUSINESS BMS Taps Maruho’s Dermatology Strength to Maximize Sotyktu Value
  September 29, 2026

• BUSINESS Lenvima-Welireg Combo Gets US Nod for Advanced RCC
  September 28, 2026

• BUSINESS Daiichi Sankyo Pulls US Filing for B7-H3 ADC in SCLC
  September 28, 2026

• BUSINESS Narcolepsy Diagnosis Still Takes Nearly 9 Years in Japan: Expert
  September 28, 2026

• BUSINESS Japan OTC Market Down for 6th Straight Month in August: Intage
  September 28, 2026

• COMMENTARY Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
  September 28, 2026

• BUSINESS IHH Unit Appeals Dismissal of 203 Billion Yen Daiichi Sankyo Suit
  September 28, 2026

• REGULATORY PMDA Suspends Review Specialist for 3 Days over Lost USB
  September 28, 2026

• REGULATORY Japan Doles Out Orphan Tags to Givinostat, Apitegromab, and Lots More
  September 28, 2026

• BUSINESS J-Pharma Inks Licensing Term Sheet for LAT1 Inhibitor JPH034
  September 28, 2026

• BUSINESS Maruho, BMS Forge Japan Marketing Alliance for Sotyktu
  September 28, 2026

• ORGANIZATION JaDHA Calls for Digital Health Seat in Chuikyo Reform
  September 28, 2026

• ORGANIZATION Digital Health Group Eager to Gain Full Seat at Chuikyo Table
  September 25, 2026

• REGULATORY MHLW Pharma Chief Eyes Wider Use of English Drug Filings to Stem Drug Loss
  September 25, 2026

• BUSINESS European Pharma Chairs Urge Policy Shift on Innovative Drug Investment
  September 25, 2026

• ORGANIZATION Japan Wholesalers’ Profit Margin Worsens to 1.04% as Costs Rise
  September 25, 2026

• ORGANIZATION Think Tank Advocates Drug Price Hikes above Existing Levels to Reflect Inflation
  September 25, 2026

• BUSINESS SymBio Inks Exclusive HHS License for BCV in Multiple Sclerosis
  September 25, 2026

• BUSINESS Tokyo Court Blocks Toho’s Poison Pill Move; Company to Appeal
  September 25, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• …
• Next ›
• 最終 »